Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
334.6 USD | +0.12% | +1.42% | +75.56% |
May. 16 | Johnson & Johnson to Buy Proteologix For $850 Million in Cash | MT |
May. 13 | Johnson & Johnson Offering Notes to Help Fund Shockwave Medical Acquisition | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 63.98 and 54.35 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+75.56% | 12.55B | B- | ||
-23.35% | 7.51B | C+ | ||
+8.51% | 6.74B | C- | ||
+14.95% | 5.48B | D+ | ||
-14.65% | 4.93B | B | ||
+30.59% | 4.71B | - | ||
-24.40% | 3.83B | B- | ||
-22.61% | 2.9B | C | ||
+49.50% | 2.49B | C- | ||
-0.50% | 1.98B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SWAV Stock
- Ratings Shockwave Medical, Inc.